Cargando…

Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery

Tumour necrosis factor (TNF)-based isolated limb perfusion (ILP) is an approved and registered treatment for sarcomas confined to the limbs in Europe since 1998, with limb salvage indexes of 76%. TNF improves drug distribution in solid tumours and secondarily destroys the tumour-associated vasculatu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brunstein, F, Rens, J, van Tiel, S T, Eggermont, A M M, ten Hagen, T L M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360755/ https://www.ncbi.nlm.nih.gov/pubmed/17106443 http://dx.doi.org/10.1038/sj.bjc.6603461

Ejemplares similares

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

Vascular disrupting agent in pancreatic and hepatic tumour allografts: observations of location-dependent efficacy by MRI, microangiography and histomorphology
por: Yin, Ting, et al.
Publicado: (2017)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity
por: Seynhaeve, A L B, et al.
Publicado: (2002)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
por: Cummings, J, et al.
Publicado: (2012)

Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma
por: Sersa, G, et al.
Publicado: (2008)

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
por: Palumbo, A, et al.
Publicado: (2011)

Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats
por: ten Hagen, T L M, et al.
Publicado: (2004)

Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery
por: Wang, Y, et al.
Publicado: (2005)

Molecular disruption of NBS1 with targeted gene delivery enhances chemosensitisation in head and neck cancer
por: Araki, K, et al.
Publicado: (2010)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours
por: Coutelle, O, et al.
Publicado: (2015)

The role of superoxide anions in the development of distant tumour recurrence
por: ten Kate, M, et al.
Publicado: (2006)

O(6)-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents
por: Walter, T, et al.
Publicado: (2015)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice
por: Ganai, S, et al.
Publicado: (2009)

Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth
por: Patel, J B, et al.
Publicado: (2007)

Stromal interaction essential for vascular endothelial growth factor A-induced tumour growth via transforming growth factor-β signalling
por: Weidenaar, A C, et al.
Publicado: (2011)

Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition
por: Byrne, N M, et al.
Publicado: (2016)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice
por: Huynh, C K, et al.
Publicado: (2006)

Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment
por: Byrne, A T, et al.
Publicado: (2009)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
por: Santoro, A, et al.
Publicado: (2010)

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
por: Di Matteo, P, et al.
Publicado: (2013)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
por: Piccirillo, S G M, et al.
Publicado: (2012)

The endothelin B (ET(B)) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification
por: Cemazar, M, et al.
Publicado: (2005)

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Oxidative stress specifically downregulates survivin to promote breast tumour formation
por: Pervin, S, et al.
Publicado: (2013)

Using macrophage activation to augment immunotherapy of established tumours
por: Fridlender, Z G, et al.
Publicado: (2013)

Photodynamic therapy-generated vaccines: relevance of tumour cell death expression
por: Korbelik, M, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_77eea9r7pn75m4lcf87fmhck85